November 13, 2019

The March of Transcatheter Aortic Valve Replacement Therapy—US Food and Drug Administration Perspectives on Device Approval for Patients at Low Surgical Risk

Key Points

Key points are not available for this paper at this time.

Abstract

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Changfu Wu

United States Food and Drug Administration

Bernard Vasseur

Rutgers, The State University of New Jersey

William H. Maisel

Electrophysiology

Journals

JAMA Cardiology

Actions

Institutions

United States Food and Drug Administration

Center for Devices and Radiological Health

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

The March of Transcatheter Aortic Valve Replacement Therapy—US Food and Drug Administration Perspectives on Device Approval for Patients at Low Surgical Risk

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study